Toward a complete dataset of drug–drug interaction information from publicly available sources  by Ayvaz, Serkan et al.
Journal of Biomedical Informatics 55 (2015) 206–217Contents lists available at ScienceDirect
Journal of Biomedical Informatics
journal homepage: www.elsevier .com/locate /y jb inToward a complete dataset of drug–drug interaction information
from publicly available sourceshttp://dx.doi.org/10.1016/j.jbi.2015.04.006
1532-0464/ 2015 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: 2432 Echo Valley Dr., Stow, OH 44224, USA. Tel.: +1 (330) 766 5310.
E-mail addresses: sayvaz1@kent.edu (S. Ayvaz), jrhorn@uw.edu (J. Horn), hassanzadeh@us.ibm.com (O. Hassanzadeh), qianzhu@umbc.edu (Q. Zhu), joh
phd@gmail.com (J. Stan), nick.tatonetti@columbia.edu (N.P. Tatonetti), sav7003@dbmi.columbia.edu (S. Vilar), mbrochhausen@uams.edu (M. Brochhausen), m
samwald@meduniwien.ac.at (M. Samwald), Mojarad.Majid@mayo.edu (M. Rastegar-Mojarad), michel.dumontier@stanford.edu (M. Dumontier), rdb20@pitt.edu (R.DSerkan Ayvaz a,⇑, John Horn b, Oktie Hassanzadeh c, Qian Zhu d, Johann Stan e, Nicholas P. Tatonetti f,
Santiago Vilar f, Mathias Brochhausen g, Matthias Samwald h, Majid Rastegar-Mojarad i,
Michel Dumontier j, Richard D. Boyce k
aDepartment of Computer Science, Kent State University, 241 Math and Computer Science Building, Kent, OH 44242, USA
bDepartment of Pharmacy, School of Pharmacy and University of Washington Medicine, Pharmacy Services, University of Washington, H375V Health Sciences Bldg, Box 357630,
Seattle, WA 98195, USA
c IBM T.J. Watson Research Center, 1101 Kitchawan Rd Route 134, P.O. Box 218, Yorktown Heights, NY 10598, USA
dDepartment of Information Systems, University of Maryland Baltimore County, Baltimore, MD 21250, USA
e Lister Hill National Center for Biomedical Communications, National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, USA
fDepartments of Biomedical Informatics, Systems Biology, and Medicine, Columbia University, 622 West 168th St VC5, New York, NY 10032, USA
gDivision of Biomedical Informatics, University of Arkansas for Medical Sciences, 4301 W. Markham St, #782, Little Rock, AR 72205-7199, USA
h Section for Medical Expert and Knowledge-Based Systems, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090
Vienna, Austria
iBiomedical Statistics & Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
j Stanford Center for Biomedical Informatics Research, Stanford, CA 94305, USA
kDepartment of Biomedical Informatics, Suite 419, 5607 Baum Blvd, Pittsburgh, PA 15206-3701, USA
a r t i c l e i n f o a b s t r a c tArticle history:
Received 22 October 2014
30 March 2015
Accepted 15 April 2015
Available online 24 April 2015
Keywords:
Drug–drug interaction
Record linkage
Natural language processing
PharmacovigilanceAlthough potential drug–drug interactions (PDDIs) are a signiﬁcant source of preventable drug-related
harm, there is currently no single complete source of PDDI information. In the current study, all publically
available sources of PDDI information that could be identiﬁed using a comprehensive and broad search
were combined into a single dataset. The combined dataset merged fourteen different sources including
5 clinically-oriented information sources, 4 Natural Language Processing (NLP) Corpora, and 5 Bioinfor
matics/Pharmacovigilance information sources. As a comprehensive PDDI source, the merged dataset
might beneﬁt the pharmacovigilance text mining community by making it possible to compare the rep-
resentativeness of NLP corpora for PDDI text extraction tasks, and specifying elements that can be useful
for future PDDI extraction purposes.
An analysis of the overlap between and across the data sources showed that there was little overlap.
Even comprehensive PDDI lists such as DrugBank, KEGG, and the NDF-RT had less than 50% overlap with
each other. Moreover, all of the comprehensive lists had incomplete coverage of two data sources that
focus on PDDIs of interest in most clinical settings. Based on this information, we think that systems that
provide access to the comprehensive lists, such as APIs into RxNorm, should be careful to inform users
that the lists may be incomplete with respect to PDDIs that drug experts suggest clinicians be aware
of. In spite of the low degree of overlap, several dozen cases were identiﬁed where PDDI information pro-
vided in drug product labeling might be augmented by the merged dataset. Moreover, the combined
dataset was also shown to improve the performance of an existing PDDI NLP pipeline and a recently pub-
lished PDDI pharmacovigilance protocol. Future work will focus on improvement of the methods for
mapping between PDDI information sources, identifying methods to improve the use of the merged data-
set in PDDI NLP algorithms, integrating high-quality PDDI information from the merged dataset into
Wikidata, and making the combined dataset accessible as Semantic Web Linked Data.
 2015 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ann.stan.
atthias.
. Boyce).
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Exposure to a potential drug–drug interaction (PDDI) occurs
when a patient is prescribed or administered two or more drugs
that can interact, even if no harm ensues [1]. ‘‘Known’’ interactions
involve drug combinations for which (a) physiological data exists
from clinical studies pointing to a potential interaction, (b) mech-
anistic assertions point toward a potential interaction, or (c) a
potential interaction can be inferred based on reasonable extrapo-
lation [2]. While exposure to a known PDDI does not always result
in an adverse drug event [3], such events are a signiﬁcant source of
preventable drug-related harm. Sixteen cohort and case-control
studies reported an elevated risk of hospitalization in patients
who were exposed to PDDIs [4]. Clinically important events attri-
butable to PDDI exposure are estimated to occur in 5.3–14.3% of
inpatients, and are responsible for 0.02–0.17% of the nearly 130
million emergency department visits that occur each year in the
United States [5,6].
At the time of this writing, there is no single complete source of
PDDI information. While several proprietary and public PDDI infor-
mation sources exist to help improve prescriber knowledge, they
differ substantially in their coverage and agreement in the inclu-
sion of PDDIs. One recent study found that only one quarter of
59 contraindicated drug pairs were listed in three proprietary
PDDI information sources [7]. Another recent study comparing
drug product labeling to the published literature for information
on pharmacokinetic DDIs found that 40% of the 44 pharmacoki-
netic drug–drug interactions affecting 25 psychotropic drugs were
located exclusively in product labeling [8]. These ﬁndings suggest
that there is a pressing need for informatics research on how to
best organize both existing and emerging PDDI information for
search and retrieval.
Several groups would beneﬁt from a more effective synthesis of
existing available PDDI knowledge. For those individuals research-
ing text mining of the pharmacovigilance literature, one possible
beneﬁt would be to enable a better understanding of the represen-
tativeness of a given natural language processing (NLP) corpus rel-
ative to all known PDDIs. A merged PDDI dataset might help
improve existing text mining algorithms by providing computable
domain knowledge. Text mining researchers might also ﬁnd the
PDDI synthesis useful for identifying gaps in PDDI information
sources that text mining might be able to address. The develop-
ment of a common PDDI framework could also beneﬁt United
States healthcare organizations who are currently striving to incor-
porate PDDI screening along with other strategies to achieve
meaningful use of electronic medical records [9,10]; drug-safety
scientists who monitor post-market data related to drug use for
new concerns [11]; researchers in drug development who build
in silico models to help identify new drug candidates or drugs that
can be ‘repositioned’ for new uses [12]; those who create and
maintain drug information resources that help clinicians guide
patients to safe and effective medication therapies [1]; and
patients seeking information on the safety of the medicines they
take [13].
The objective of the project described here was to assess the
feasibility and potential value to different stakeholders of inter-
linking all publicly available PDDI data sources using a common
data model. We ﬁrst conducted a comprehensive and broad search
of public PDDI knowledge sources. We then established links
between the PDDI sources and evaluated their information cover-
age. This resulted in single integrated PDDI dataset, and list of
the speciﬁc data elements provided by each source. Finally, we
conducted some preliminary analyses of the potential value of
the merged dataset. These included (1) examining the overlap
between the data sources including existing NLP corpora relativeto other PDDI datasets, (2) testing if the PDDI dataset could
improve the performance of a PDDI NLP algorithm, (3) examining
cases where PDDI information provided in drug product labeling
might be augmented by the merged dataset, and (4) testing if the
combined dataset would improve the performance of a recently
published pharmacovigilance protocol [14].2. Materials and methods
2.1. Survey of DDI data sources
The scope of the PDDI source search included drug interaction
lists designed for use in clinically oriented applications, annotated
text corpora used for NLP research, knowledge bases used for clin-
ical and translational research, and suspected PDDI associations
(i.e., pharmacovigilance signals) [15]. We searched for all poten-
tially relevant resources by querying bibliographic databases
(PubMed and Google Scholar), reviewing the tertiary literature,
and scanning conference proceedings for papers describing
drug-related resources. This search was augmented by requests
for input from members of various pharmacoinformatics and
chemoinformatics interest groups and maintainers of major
meta-repositories for RDF data such as Bio2RDF [16]. We then
manually inspected each potentially relevant resource to deter-
mine if it (1) supported NLP experiments, (2) provided information
for use by clinicians, or (3) supported bioinformatics or
pharmacovigilance research. These three categories were chosen
because we think that they cover the three primary use cases for
PDDI knowledge. We considered the resources that are
non-proprietary and represented as structured data or require
minimal efforts to structure. Fig. 1 demonstrates the resources
within each category and an overview of the study framework.2.2. Data element survey
We acquired all publicly available PDDI datasets identiﬁed by
the aforementioned search and then designed a simple PDDI data
model (i.e., an associative array or ‘‘dictionary’’) to combine the
data elements provided from each source. We then developed cus-
tom scripts to translate the PDDIs listed in each source to the
model. This activity and all analyses described below were con-
ducted between June and September 2014 using the versions of
the data sets current at that time.2.3. Analysis of the overlap between the data sources
With the goal of integrating publicly available PDDI datasets,
we ﬁrst performed an analysis of the overlap between drug entities
found across the sources. The ﬁrst step in this analysis involved
identifying attributes across the sources that could be used to
match records that refer to the same drug entity (i.e., linkage
points). Because our goal was to facilitate drug mapping across dif-
ferent drug resources while avoiding erroneous mappings, we
restricted linkage points to:
 Existing mappings where one source provided an unambiguous
drug identiﬁer from another source (e.g., Source A provides the
exact unique identiﬁer for drug X in Source B).
 An exact case insensitive match of the string name or synonym
for the drug as provided in two sources.
 An intermediate source provided a data item (e.g., a chemical
structure string) that could be used to create an unambiguous
mapping between a drug entity to other sources.
Fig. 1. Potential drug–drug interaction information resources included in the study and an overview of the study framework.
208 S. Ayvaz et al. / Journal of Biomedical Informatics 55 (2015) 206–217Drug entities in each dataset were mapped to DrugBank identi-
ﬁers [17] wherever possible to enable cross-dataset comparisons.
DrugBank was chosen for this purpose because of its broad inclu-
sion of drugs, including drugs marketed in different countries.
The resource also provides a variety of identiﬁers for drugs includ-
ing string names, codes from various terminologies, and chemical
structure identiﬁers.
Once the drug entities used by each source was mapped to
DrugBank we use simple counts and percentages to compare
PDDI overlap. We created a tabular representation of the results
so that the overlap of the datasets, including those supporting
NLP experiments, could be easily compared with each other. We
also queried the merged dataset to identify speciﬁc PDDI instances
that were in common across sources.1 https://github.com/dbmi-pitt/pk-ddi-role-identiﬁer/tree/master/nlp-ddi-role-
identiﬁer.2.4. Testing if the PDDI dataset could improve the performance of a
PDDI NLP algorithm
We tested if a merged PDDI dataset could improve the perfor-
mance of the existing PDDI NLP pipeline created by Bui et al
[18]. The Bui pipeline was chosen because (1) its performance is
well characterized for three different NLP corpora, and (2) the code
implementing the pipeline is available as an open source project.
The system uses three steps to classify sentences for the mention
of a PDDI. First, it pre-processes the input text to convert input sen-
tences into a structured representation. During this phase, the sen-
tence text is scanned to identify ‘‘trigger’’ words from a list of more
than 200 words similar to ‘‘alteration’’, ‘‘blocked’’, ‘‘caused’’, and
‘‘potentiated.’’ Sentences for which no trigger words are found
are dropped from further processing. Sentences that mention trig-
ger words are mapped into a suitable syntactic structure and then
used to generate feature vectors. The third step in the process is to
use the obtained feature vectors to train a support vector machine
(SVM) classiﬁer.
We added one additional step during pre-processing for those
sentences that lacked a trigger word. Rather than simply exclude
the sentence, a version of the merged PDDI dataset was queried
for each drug pair mentioned in the sentence. If the query returned
a result, the associated sentence was passed to the remaining steps
of the NLP pipeline. Our reasoning for this approach is that the list
of trigger words compiled by the Bui et al. might be an imperfect
ﬁlter for PDDI NLP because it arose from their research on NLP of
protein–protein interactions. We expected that there might be
cases where a PDDI mention uses terms not present in the triggerlist. In those cases, the presence in the merged PDDI dataset of a
drug pair from the sentence might be sufﬁcient ‘‘domain knowl-
edge’’ to justify retaining the sentence for further NLP.
We altered the code written by Bui et al. [18] to use the test
method when ﬂagged. We then tested the Bui pipeline using the
NLP corpora that they used in their original evaluation, both with
and without the use of the merged PDDI dataset during
pre-processing. The merged PDDI dataset used for testing the
approach was slightly different from the one used to compare
PDDI overlap (Section 2.3). Speciﬁcally, datasets that included
the exact same set of PDDIs as the two NLP corpora were
excluded. Also excluded were PDDI datasets generated using
NLP or by pharmacovigilance signal generation. These were
excluded because the number of false positives in these datasets
is not known. All tests were run on a 64-bit Dell XPS conﬁgured
with Ubuntu Linux 14.04 and using Java 1.7.0_72. The source code
for the modiﬁed NLP pipeline was made available for download to
interested researchers.12.5. Augmenting PDDI information in Drug Product Labeling
The drug product label, also known as a ‘‘package insert’’ in the
United States (US) and the summary of product characteristics in
Europe, is a document required by law, written for clinicians and
patients containing information on the drug by the drug manufac-
turers. In this respect, it differs from an NLP corpus, which is a large
collection of texts, written or spoken material upon which a lin-
guistic analysis is based and used in the development of NLP tools,
and a knowledge base, which is a technology used to store complex
structured and unstructured information used by a computer sys-
tem. US Drug product labeling information is provided to the pub-
lic for free by the National Library of Medicine DailyMed web site.
Once all datasets were interlinked by DrugBank identiﬁers, we
investigated the potential value of the interlinked dataset for aug-
menting PDDI information provided in drug product labeling.
Studies have shown product labeling to be incomplete [19, 20]
and one motivation for this activity is to extend previous pilot
work on methods to address known limitations of the information
source [21]. To do this, we examined cases where there existed an
overlap between the PDDI datasets designed for NLP research with
product labeling and other data sources.
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interactions
We tested the potential value of the interlinked PDDI dataset for
improving the performance of a pharmacovigilance protocol for
making PDDI predictions [14]. The protocol generates new PDDI
candidates through the integration of chemical, structure, and drug
interaction similarity measures via linear algebra techniques. The
protocol speciﬁes that drug interaction similarity measures should
be integrated into a reference standard of well-established PDDIs.
To apply the protocol, the drugs described in the different sources
were mapped to 928 DrugBank drugs used in previous studies for
which the chemical and structure similarity information had
already been calculated.
A key component of the protocol is a PDDI reference standard
that is representative of the many different mechanisms by which
drug–drug interactions might occur. We experimented with four
different methods for creating such a reference standard: (1) com-
bining all clinically oriented applications (except one left out for
validation, see below), (2) combining all text corpora developed
for NLP research, (3) combining all knowledge bases used for bioin
formatics/pharmacovigilance, and (4) combining all datasets into a
single dataset.
The performance of the protocol using each dataset as the refer-
ence PDDI knowledge base was evaluated by comparing the list of
predicted PDDIs with a list of PDDIs from the VA NDF- RT [22] – a
dataset that, until September of 2014, covered all drugs used in
United States Veteran’s Administration (VA) formulary. Plots of
area under the receiver operating characteristic (ROC) curves were
used for performance comparisons. We selected the VA NDF-RT as
the comparison information source because it was designed to be a
comprehensive and clinically-oriented PDDI information source.
Some drug–drug interactions data sources, such as DrugBank, con-
tain sets of theoretical DDIs with limited implications at clinical
level.3. Results
3.1. Survey of DDI Data Sources
Our systematic search identiﬁed 14 publicly available sources of
PDDIs (Table 1).
 Five of the sources were developed for clinical application:
CredibleMeds [23] – a list of PDDIs thought to be clinically
relevant and supported by strong scientiﬁc evidence; VA
NDF- RT [22] – a list of PDDIs formerly maintained by the
United States Veteran’s Administration (VA) for use in VA care
settings; ONC High Priority [24] – a list of PDDIs suggested as
a high priority to alert clinicians in any care environment;
ONC Non-interruptive [25] – a list of PDDIs not requiring inter-
ruptive alerting in any care environment; and OSCAR – a list of
PDDIs derived by expert consensus in the late 1990s [26] that
were more recently used in an Open Source Electronic Health
Records system called OSCAR [27].
 Four of the sources were developed to support NLP algorithm
development: DDI Corpus 2011 [28] – the reference standard
for the 2011 DDIExtraction Challenge on drug–drug interaction
NLP; DDI Corpus 2013 [29] the reference standard for the 2013
SemEval DDIExtraction Challenge that followed the 2011 chal-
lenge; PK DDI Corpus [30] – a reference standard used to
develop NLP to identify pharmacokinetic PDDIs mentioned in
product labeling; and NLM CV DDI Corpus [31] – a reference
standard used to develop NLP to identify PDDIs mentioned in
drug product labeling affecting cardiovascular drugs. Five other sources were developed to support either pharma-
covigilance or bioinformatics applications. KEGG DDI [32] – a
list provided by the Kyoto Encyclopedia of Genes and
Genomes (KEGG) resource [33] of PDDIs extracted from the
interaction tables of Japanese product labels; TWOSIDES [15]
– a list of PDDI pharmacovigilance signals derived by data min-
ing a database of spontaneously reported adverse events;
DrugBank – PDDIs listed in v4.0 of DrugBank [17]; DIKB –
observed and predicted pharmacokinetic interactions listed in
the Drug Interaction Knowledge Base [34]; and SemMedDB –
a database of subject, predicate, object relationships extracted
from MEDLINE abstracts by the NLP program SemRep [35].
For this project, all ‘‘INTERACTS_WITH’’ relationships between
two drugs were treated as PDDIs.
Four non-NLP sources were comprehensive in their identiﬁca-
tion of PDDIs across all drugs (VA NDF-RT, DrugBank, TWOSIDES,
KEGG DDI and SemMedDB). Of these, only the VA NDF-RT was
designed for use in a clinical setting. TWOSIDES was the only phar-
macovigilance signal source. Both KEGG DDI and SemMedDB were
generated by automated text extraction methods.
One source developed for NLP (DDI Corpus 2011) was derived
primarily from data available in DrugBank at the time it was cre-
ated while another source (DDI Corpus 2013) included DrugBank
PDDIs and PDDIs identiﬁed in a sample of a few hundred abstracts
present in MEDLINE. Another NLP corpus (PK DDI Corpus) was
intended to be a representative sample of statements in product
labels describing pharmacokinetic PDDIs. The fourth NLP corpus
(NLM CV DDI Corpus) focused on all types of PDDIs involving car-
diovascular drugs.
The remaining sources focused on PDDIs of a certain severity
(CredibleMeds), clinical importance (ONC High Priority and ONC
Non-interruptive), mechanism of interaction (DIKB), or frequency
of prescription (OSCAR). To elaborate the meaning of severity con-
cept, it can be described as a label qualifying the relative impor-
tance of a PDDI. For example, the VA NDF-RT system assigned a
severity level of ‘‘Critical’’ for PDDIs that were thought by the sys-
tem’s developers to be of generally greater concern than those
labeled as ‘‘Signiﬁcant’’.
3.2. Data element surveys
Table 2 shows a combined view of the data elements provided
from each PDDI source. The data elements provided varied consid-
erably depending on the source. CredibleMeds was the most com-
prehensive in terms of variety of data elements and was the only
non-NLP source to provide management options. Two of the NLP
sources provided a tag that could be used to determine if a PDDI
mention described management options. In DDI Corpus 2013 the
tag was ‘‘advise’’ while the tag was ‘‘Caution Interaction’’ in the
NLM DDI Corpus.
All resources that provided a description of the PDDI (including
NLP sources) did so as unstructured text. Four non-NLP sources
(CredibleMeds, KEGG, DrugBank, and DIKB) provided some men-
tion of PDDI mechanism (e.g., enzyme inhibition) but only two
sources (KEGG and DIKB) provided this information as a term from
an ontology (thus, making it interpretable by a computer). Two of
the NLP sources provided tags that could be used to determine if a
PDDI mention explained the mechanism of the interaction. In DDI
Corpus 2013 the tag was ‘‘mechanism’’, while the tags ‘‘Increase_
Interaction’’ and ‘‘Decrease_Interaction’’ were used in the NLM
DDI Corpus. No such tag was provided by the PK DDI Corpus but
all PDDIs provided by this source occurred by the mechanism of
enzyme inhibition.
The clinical effect ﬁelds were computable in only one of the four
sources that provided such data (TWOSIDES). DDI Corpus 2013
Table 1
List of PDDI Data Sources – A short description of publicly available PDDI sources including the number of PDDIs in the original data extraction (denominator) and the number of
PDDIs that we could map to DrugBank (numerator). Counts for mapped PDDIs are on unique interacting pairs without consideration of other data elements and with no
distinction of the precipitant or object of the interaction.
Source Description Mapped/original Category Data owner/maintainer Frequency of
updates
Crediblemeds.org A list of clinically important drug–drug
interactions
82/83 Clinically-oriented Crediblemeds.org As needed
VA NDF-RT PDDIs used until 2014 by the Veteran’s
Administration health care system
2606/5265 Clinically-oriented Veterans Health
Administration
No future updates.
Discontinued
ONC High Priority A consensus list of PDDIs that are
recommended by the Ofﬁce of the
National Coordinator as high priority
for inclusion in alerting systems
1150/1150 Clinically-oriented ONC One-time
ONC Non-interruptive A consensus list of PDDIs that are
recommended by the Ofﬁce of the
National Coordinator for use in
non-interruptive alerts
2101/2101 Clinically-oriented ONC One-time
OSCAR PDDIs used on an open source
electronic health records system
7969/7969 Clinically-oriented Oscar McMaster EMR One-time
DDI Corpus 2011 Training corpus for the 2011 SemEval
PDDI text extraction challenge
586/3160 NLP Corpora Isabel Segura-Bedmar One-time
DDI Corpus 2013 Training corpus for the 2013 SemEval
PDDI text extraction challenge
1287/5021 NLP Corpora Isabel Segura-Bedmar One-time
PK DDI Corpus Training corpus for NLP to extract
pharmacokinetic PDDIs from all drug
product labels
166/298 NLP Corpora Richard D. Boyce One-time
NLM CV DDI Corpus Training corpus for NLP to extract all
PDDIs from cardiovascular drug
product labels.
247/2963 NLP Corpora National Library of
Medicine
One-time
KEGG DDI PDDIs extracted from the interaction
tables of Japanese product labels
26,664/298,337 Bioinformatics–Pharmacovigilance Kanehisa Laboratories As needed
TWOSIDES Pharmacovigilance signals indicative of
possible associations between drug
combinations and adverse events
9921/63,473 Bioinformatics–Pharmacovigilance Nicholas Tatonetti One-time
DrugBank Comprehensive drug information
resource
12,113 Bioinformatics–Pharmacovigilance DrugBank .ca Roughly
bi-annual
DIKB An evidence-focused knowledge base
of pharmacokinetic PDDIs
561/561 Bioinformatics–Pharmacovigilance Richard D. Boyce Periodic
SemMedDB PDDIs extracted by NLP from the titles
and abstracts in PubMed
3952/190,219 Bioinformatics–Pharmacovigilance National Library of
Medicine
As needed
Table 2
Data elements provided by publicly available PDDI sources.
Data element Credible
Meds
NDF-RT ONC
High
Priority
ONC
Non-interruptive
OSCAR DDI
Corpus
2011
DDI
Corpus
2013
PK DDI
Corpus
NLM DDI Corpus KEGG TWO-SIDES Drug-Bank DIKB Sem
MedDB
Conﬁdence value x
Description x x x x x x x
Clinical effect x x x xa
Citation of evidence x xa x
Management options x x x
Mechanism x x x xa xd xa
Modality x
Precipitant/object
distinctione
xa x x x x x x xa
Related drugs x
severity concept xa,b x x x xc
a Data element is computable rather than in unstructured text.
b Critical or severe.
c Precaution or contraindicated.
d Available on the public website but not explicitly in the downloadable data.
e The individual drugs involved in PDDI were tagged as having either the precipitant or object role.
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clinical effect. However, records from the source provided no other
semantic relationships such as a concept from a biomedical termi-
nology indicating the clinical effect.
Considering data elements that were unique to a single source,
TWOSIDES was the only source to provide a conﬁdence value for its
PDDI-adverse event associations. A conﬁdence value is a
real-valued number representing the level of certainty that apharmacovigilance drug safety signal is real. We note that it is also
the only pharmacovigilance signal source present in this analysis.
PK DDI Corpus was the only source to include drug pairs that are
known tonot interact byusing the ‘‘modality’’ tag to distinguish pos-
itive fromnegative PDDIs. Finally, CredibleMedswas the only source
to list other drugs associatedwith the anticipated effect of the PDDI.
This information is important in cases where a clinicianmust assess
if an ADE occurring in a patient is associated with a PDDI [36].
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We analyzed overlap between the subset of the PDDIs in the
public data sources shown in Table 1 for which both drugs involved
in an interaction could be mapped to DrugBank. Here we provide a
brief summary of the mapping procedure and then summarize the
results.
For the ONC High Priority PDDIs and ONC Non-Interruptive
PDDIs, we manually extracted the PDDIs from the publications
[24], [25]. The extracted list often mentioned drug class interac-
tions rather than individual drugs. Our pharmacy experts helped
identify the drugs belonging to each class. Another recent study
[37] has also identiﬁed the same individual drugs within each drug
class of ONC High Priority PDDIs, short of QT Prolonging agents. For
QT Prolonging agents in ONC High Priority list, we obtained the list
of agents with a known risk of torsades de pointes (TdP) provided
by Crediblemeds.org with the directions of our pharmacy experts.
We then mapped drug names from the two sources to DrugBank
entities using an exact string match on DrugBank names and syn-
onyms. PDDIs from CredibleMeds were manually extracted and
mapped to DrugBank entries in the same way.
DrugBank provides KEGG drug identiﬁers for many drugs that
we used as a mapping. Similarly, TWOSIDES uses PubChem drug
identiﬁers that are included within many DrugBank drug
records. Drugs in the DIKB were already identiﬁed by DrugBank
identiﬁers so no mapping was required.
The remaining mappings were done by identifying intermediate
mappings that could serve as a bridge between the source and
DrugBank. In particular, we use the Unique Ingredient Identiﬁers
(UNII) list provided by the FDA that contains a list of preferred
substance names, synonyms, chemical structure strings, and UNII
codes for drugs. The ﬁrst step was to match active ingredient
strings from RxNorm [38] with the UNII preferred terms using a
case insensitive string match because this was formerly reported
as a viable method in RxNorm documentation [39]. With this
robust mapping, we then sought to perform an automated
mapping of FDA Unique Ingredient Identiﬁers to DrugBank based
on our previous work interlinking these sources [40]. The ﬁnal
FDA UNII to DrugBank mappings were manually reviewed for
accuracy.
We developed two different approaches that were based on fact
that a large number of drugs in both the UNII list and DrugBank
contain IUPAC International Chemical Identiﬁers (InChI) [41]. One
approach was more conservative and limited matches between a
DrugBank and UNII record to those cases where an exact
case-insensitive match was identiﬁed for both an InChI identiﬁer
and either the drug preferred term or synonym. A less conservative
approach involves a match on InChI key or an exact
case-insensitive match of preferred term or a synonym. The latter
approach resulted in a greater number of mappings (1613 and
2139 mappings respectively). We report the overlap analysis based
on the latter mapping approach.
The OSCAR list of PDDIs used ATC codes for drug identiﬁers. We
utilized a mapping from ATC codes to RxNorm drug identiﬁers
available in the OMOP/IMEDS Standard Vocabulary (version 4)
[42]. We then used our mapping of RxNorm to DrugBank via the
UNII list. In cases where the ATC codes provided by Oscar were
more general than just a single drug, our drug experts helped iden-
tify the drug speciﬁc identiﬁers to link back to DrugBank. Similarly,
the NDF-RT interactions were mapped by combining a mapping of
the NDF-RT to RxNorm present in the Uniﬁed Medical Language
System(UMLS) [43], and then mapping from RxNorm to
DrugBank via the UNII list. PK DDI Corpus mappings were also
done using the samemethod described above; identifying interme-
diate mappings and linking drugs with RxNorm identiﬁers to
DrugBank.In the case of SemMedDB, we extracted all ‘‘INTERACTS_WITH’’
predictions from SemMedDB, which provides UMLS Concept
Unique Identiﬁers (CUI) for both concepts in the interaction predic-
tion. As UMLS CUIs are not limited to drugs, we only exploited the
CUIs where both interacting concepts could be mapped to drugs
with RxNorm CUIs. After mapping to RxNorm, we followed the
same aforementioned methodology for linking drugs with
RxNorm identiﬁers to DrugBank.
The ‘‘mapped/original’’ columns of Table 1 show both the orig-
inal number of PDDIs for each data source and the number of
PDDIs that remained after mapping to DrugBank. While most map-
pings are complete, there are differences between mapped/original
counts in some resources (e.g., VA NDF-RT, KEGG, and TWOSIDES).
The main reason behind the discrepancy between mapped and
unmapped PDDIs is the PDDI duplication in the original sources.
Under ‘‘mapped’’ PDDIs, we only consider the unique pair of drugs
in the PDDI regardless of their position as object or precipitant. For
instance, PDDI between Acetylcholine and Morphine was reported
20 times in SemMedDB by different studies. However, we consider
it as a single mapped PDDI. Similarly, the PDDI pair of Carnitine
and Bupropion was reported in association with 47 different
adverse events in TWOSIDES. In KEGG, there were duplications
due to directionality of the PDDI drug pairs. Also, the KEGG PDDI
mapping relies on the cross reference links between DrugBank ID
to KEGG ID provided in DrugBank. Since we currently have no
other direct way of mapping KEGG drugs to DrugBank, we could
only map the KEGG PDDIs, where both drugs involved in PDDIs
with DrugBank cross reference links. In the future, we might
explore alternative methods for improving mapping between
KEGG and DrugBank such as text parsing and string matching
techniques.
The DDI Corpora, PK DDI Corpus, NLM Corpus are designed for
NLP text mining purposes. Hence, they only have drug names as
drug identiﬁer that can be utilized for mapping process. For map-
ping from these data sources, we used exact string matching on the
drug names, synonyms and brand names (see above). However,
some of the PDDIs from the NLP resources were not mappable as
they contained PDDIs that were speciﬁed as metabolites, groups
of chemicals, or drug classes rather than individual drugs. The
number of drug groups or classes that were listed in one or both
of the drugs in the PDDIs was 288 in the DDI 2011 Corpus, 445
in DDI 2013 Corpus and 493 in the NLM PDDI Corpus. Out of the
drugs groupings in these resources, there were many instances of
atypical, ambiguous and error-prone drug group mentions such
as ‘‘drugs that are commonly taken by the elderly’’, ’’drugs that
have a narrow therapeutic range’’, ’’centrally acting drugs’’, ‘‘drugs
that are actively secreted by the kidney has not been investigated
in humans’’. Therefore, we limited the mapping process to the indi-
vidual drugs from the aforementioned resources.
Table 3 shows the pairwise overlap between the fourteen
sources. The largest overlap in terms of PDDI count was between
DrugBank and KEGG (2143 PDDIs). In terms of average percentage
overlap, DrugBank and KEGG covered the most drug pairs across
other sources (28.6% and 25.6% respectively). The greatest percent-
age of PDDIs covered by another source was DDI Corpus 2013’s
coverage of DDI Corpus 2011 (535 PDDIs, 91.3%) followed by the
DrugBank’s coverage of the CredibleMeds (57 PDDIs, 69.1%).
Three data sources had no overlap with CredibleMeds (PK DDI
Corpus, TWOSIDES, and SemMedDB) and ONC-Non-interruptive
had no overlap with DIKB.
Each of the NLP datasets had very little overlap with the
clinically-oriented datasets. The greatest overlap was between
DDI Corpus 2013 and the VA NDF-RT with 295 PDDIs in common
(11.4% of the NDF-RT and 22.9% of the DDI Corpus 2013). The over-
lap between the NLP datasets and the two clinical datasets that
focused on PDDIs of high clinical importance was much less.
Table 3
Overlap between publicly available PDDI datasets for those drug pairs that could be mapped to DrugBank in both dataset.
SemMedDB
Credible Meds 0 Credible
Meds(0.0%, 0.0%)
NDF-RT 69 16 NDF-RT
(2.7%, 1.7%) (0.6%, 19.5%)
ONC High Priority 12 8 225 ONC High
Priority(1.0%, 0.3%) (0.7%, 9.8%) (19.6%, 8.7%)
ONC Non-
interruptive
8 4 27 2 ONC Non-
interruptive(0.4%, 0.2%) (0.2%, 4.9%) (1.3%, 1.0%) (0.1%, 0.2%)
OSCAR 124 23 201 44 861 OSCAR
(1.6%, 3.1%) (0.3%, 28.0%) (2.5%, 7.7%) (0.6%, 3.8%) (10.8%, 41.0%)
DDI Corpus 2011 68 4 162 13 4 67 DDI Corpus
2011(11.6%,
1.7%)
(0.7%, 4.9%) (27.6%, 6.2%) (2.2%, 1.1%) (0.7%, 0.2%) (11.4%,
0.8%)
DDI Corpus 2013 114 5 295 23 5 112 535 DDI Corpus
2013(8.9%, 2.9%) (0.4%, 6.1%) (22.9%,
11.4%)
(1.8%, 2.0%) (0.4%, 0.2%) (8.7%, 1.4%) (41.6%,91.3%)
PK DDI Corpus 12 0 50 1 1 22 28 51 PK DDI
Corpus(7.2%, 0.3%) (0.0%, 0.0%) (30.1%, 1.9%) (0.6%, 0.1%) (0.6%, 0.0%) (13.3%,
0.3%)
(16.9%, 4.8%) (30.7%, 4.0%)
NLM Corpus 35 3 50 9 2 33 48 80 26 NLM Corpus
(14.2%,
0.9%)
(1.2%, 3.7%) (20.2%, 1.9%) (3.6%, 0.8%) (0.8%, 0.1%) (13.4%,
0.4%)
(19.4%, 8.2%) (32.4%, 6.2%) (10.5%,15.7%
KEGG 403 27 777 159 511 844 218 419 77 104 KEGG
(1.5%,
10.2%)
(0.1%, 32.9%) (2.9%, 29.9%) (0.6%, 13.8%) (1.9%, 24.3%) (3.2%,
10.6%)
(0.8%, 37.2%) (1.6%, 32.6%) (0.3%, 46.4% (0.4%,
42.1%)
TWOSIDES 51 0 82 25 40 101 14 25 11 6 724 TWOSIDES
(0.5%, 1.3%) (0.0%, 0.0%) (0.8%, 3.2%) (0.3%, 2.2%) (0.4%, 1.9%) (1.0%, 1.3%) (0.1%, 2.4%) (0.3%, 1.9%) (0.1%, 6.6%) (0.1%, 2.4%) (7.3%, 2.7%)
DRUGBANK 150 57 1296 319 180 490 213 448 75 111 2143 289 DRUG BANK
(1.2%, 3.8%) (0.5%, 69.5%) (10.7%,
49.9%)
(2.6%, 27.7%) (1.5%, 8.6%) (4.0%, 6.1%) (1.8%, 36.3%) (3.7%, 34.8%) (0.6%, 45.2% (0.9%,
44.9%)
(17.7%,
8.0%)
(2.4%, 2.9%)
DIKB 2 21 85 33 0 7 25 36 16 8 152 69 189
(0.4%, 0.1%) (3.7%, 25.6%) (15.2%, 3.3%) (5.9%, 2.9%) (0.0%, 0.0%) (1.2%, 0.1%) (4.5%, 4.3%) (6.4%, 2.8%) (2.9%, 9.6%) (1.4%, 3.2%) (27.1%,
0.6%)
(12.3%,
0.7%)
(33.7%,
1.6%)
Two percentages are shown, the ﬁrst representing the percentage of PDDIs in the row-mention that overlapped with the column-mention, the second vice-versa. Becaus most datasets did not distinguish precipitant and object
drugs, PDDI drug pairs were compared without consideration of the directionality of the interaction.
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Table 4
A comparison of the performance of a previously published NLP pipeline for PDDIs with and without using a version of the merged PDDI dataset during the pre-processing phase
of the pipeline.
DrugBank 2011 (DDI Corpus 2011) DrugBank 2013 (DDI Corpus 2013) Medline 2013
Precision (%) Recall (%) F1 (%) Precision (%) Recall (%) F1 (%) Precision (%) Recall (%) F1 (%)
Original NLP pipeline 68.56 71.92 70.20 85.87 81.11 83.42 67.57 52.63 59.17
Modiﬁed PDDI pipeline 68.59 72.58 70.53 85.65 81.67 83.61 65.79 52.63 58.48
Fig. 2. ROC curves for VA NDF-RT dataset evaluated with the DDI models (Clinical,
NLP Corpora and Bioinformatics models). The data related to the previous 3 models
were combined to form the Common Data Model (CDM).
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represented only 2% of the PDDIs in the ONC High Priority source
and 6% of the PDDIs in the CredibleMeds source. As was mentioned
above, the overlap between the DDI Corpus 2011 and DDI Corpus
2013 was very high. However, the DDI Corpus 2013 represented
slightly less than 1/3rd of the PDDIs present in the PK DDI
Corpus, and roughly the same proportion of the PDDI present in
the NLM Corpus.
Examining overlap across multiple sources, we found no PDDIs
common to all 14 sources, only one PDDI (Rifampin/Bisoprolol)
common to all four NLP sources, and only four PDDIs
(Haloperidol/Clozapine, Triazolam/Voriconazole, Triazolam/
Fluconazole, Midazolam/Fluconazole) common to the Bioinformati
cs/Pharmacovigilance sources. The Clinically-oriented information
sources had PDDIs common to at most three sources, with the
combination NDF-RT, ONC-HighPriority and OSCAR resulting in
the greatest overlap (24) in this category. The number of PDDIs com-
mon to any three sources varied depending on which sources were
selected. CredibleMeds, NDF-RT, ONC-Non Interruptive List had no
common PDDIs, while DDI Corpus 2011, DDI Corpus 2013, and
NLM CV Corpus had 38.3.4. Testing if the PDDI dataset could improve the performance of a
PDDI NLP algorithm
The version of the merged PDDI dataset that was used for NLP
testing retained all of the original datasets except DDI Corpus
2011, DDI Corpus 2013, DrugBank, SemMedDB, KeGG, and
TWOSIDES. The ﬁrst two were excluded because they were exactly
the same datasets as two of the NLP corpora used by Bui et al. for
evaluation of their pipeline. DrugBank was excluded because it was
used to create the two NLP corpora. The last three datasets were
excluded because the number of false positives in these datasets
is not known.
Table 4 shows a comparison of the performance of a previously
published NLP pipeline for PDDIs, with and without using a version
of the merged PDDI dataset during the pre-processing phase of the
pipeline. As measured by the balanced F measure, using a the
merged PDDI dataset in the pre-processing phase led to a slight
performance improvement for the two DrugBank NLP datasets
but a slight decrease for the MedLine dataset. The improved perfor-
mance for the DrugBank datasets was primarily associated with an
increased in recall of true PDDI mentions. No increase or decrease
in recall was observed for the MedLine dataset.2 http://purl.org/net/drug-interaction-knowledge-base/PDDI-data-merged-
conservative.
3 http://purl.org/net/drug-interaction-knowledge-base/PDDI-data-merged-non-
conservative.
4 http://purl.org/net/drug-interaction-knowledge-base/PDDI-data-merging-
project.3.5. Augmenting PDDI information in drug product labeling
The number of cases where PDDI information extracted from
drug product labeling might be automatically augmented by other
sources is shown in Table 3 in the cells where either of the two NLP
datasets that focus on product labeling (PK DDI Corpus and NLM
Corpus) intersects other information sources. In general, the per-
centage overlap was less than 50%. The greatest percentage of
overlap was between the PK DDI Corpus and KEGG (46.4%), fol-
lowed by PK DDI Corpus and DrugBank (45.2%), and NLM Corpus
and DrugBank (44.9%).3.6. Applying the merged PDDI sources to predict new potential
interactions
Fig. 2 shows that the PDDI pharmacovigilance protocol per-
forms better using the combined CDM list of PDDIs as a reference
standard than with just the clinical, NLP, or bioinformatics/pharma
covigilance datasets (AUROC = 0.80 vs 0.74, 0.79, and 0.79
respectively).4. Discussion
To the best of our knowledge, while there has been related
work comparing PDDI information sources (see below), this is
the ﬁrst study to attempt to bring together all publically available
sources of PDDI information into a single dataset. A systematic
search identiﬁed 14 public data sources shown in Table 1. The
merged dataset2 ,3, and code4 used to create it, is available for
download for research purposes.
An analysis of the overlap of PDDIs from the datasets with drugs
that could be mapped to DrugBank identiﬁers found that there is
very little overlap between or across publicly available PDDI
resources. For many pairwise comparisons, the percentage of over-
lap was limited by the relatively small size of one of the datasets.
For example, three data sources had no overlap with
CredibleMeds which listed only 83 interactions. However, even
comprehensive PDDI lists such as DrugBank, KEGG, and the
NDF-RT had less than 50% overlap with each other. Moreover, all
of the comprehensive lists had incomplete coverage of two
clinically-oriented sets that focus on PDDIs of interest in most clin-
ical settings (The two ONC lists [24,25] and CredibleMeds [23]).
Our ﬁnding of low agreement across public sources providing
PDDI information is concordant with other studies, including the
two mentioned in the introduction [7,8]. Most relevant to the cur-
rent study, Peters, Bodenreider, and Bahr mapped drugs in the VA
NDF-RT, DrugBank, and ONC High-priority list to RxNorm and then
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lap between the PDDIs listed in the VA NDF-RT and DrugBank. This
same study found that roughly 60% of the ONC PDDIs were present
in the VA NDF-RT, with roughly the same proportion present in
DrugBank. We note that the level of overlap they found, while still
low, was considerably higher than what was found in the current
study. We think that the main reason for this is that we expanded
the ONC High-priority list to include all agents with a known risk
of torsades de pointes (TdP) as provided by Crediblemeds.org
(see Section 3.3). Thus, the ONC High-priority list used in the cur-
rent study had more than three times the number of PDDIs than
that used in the Peters study (1150 vs 360).
Disagreement among sources of PDDI information has been
known for more than a decade [44] and much work has been done
in recent years to better understand the underlying reasons [1].
Many reasons have been identiﬁed by drug interaction experts
including the need for a more standard way to assess the evidence
that a drug combination can actually result in an interaction,
agreement about how to assess if an interaction applies to a single
drug or all drugs in its class, and guidance on how a drug informa-
tion source should handle PDDIs listed in product labeling [2]. We
would suggest adding to these reasons that there is currently no
interoperable standard for representing PDDIs and associated evi-
dence in a computable form (i.e., as assertions linked to evidence).
Since evidence for PDDIs is distributed across several resources
(e.g., product labeling, the scientiﬁc literature, case reports, social
media), editors of drug information resources (public or propri-
etary) must resort to ad hoc information retrieval methods that
can yield different sets of evidence to assess. Based on this infor-
mation, we think that systems that provide access to the compre-
hensive lists, such as APIs into RxNorm [37], should provide
results using a interoperable common data model for PDDIs, while
also being careful to inform users that the lists may be incomplete
with respect to PDDIs that drug experts suggest clinicians be
aware of.
We tested a very basic approach to integrating the PDDI dataset
into an existing NLP pipeline and found that it slightly improved the
pipeline’s performance on two of the three NLP datasets. We take
this as evidence that the merged dataset has potential to improve
PDDI NLP, but that more research is necessary to determine the
optimal integration method. In our simple test, the PDDI dataset
was used as a second check before ﬁltering out sentences that were
unlikely to be informative for training a machine learning classiﬁer
because they lacked ‘‘trigger’’ words. For example, without the
method, sentences such as the following would be excluded from
use in training the NLP classiﬁer for the DrugBank 2013 NLP corpora
(DDI Corpus 2013 in the current study):
‘‘If at all possible guanethidine should be discontinued well
before minoxidil is begun.’’
‘‘Theophylline: Grepaﬂoxacin is a competitive inhibitor of the
metabolism of theophylline.’’
‘‘Dose adjustment of Sensipar may be required and PTH and
serum calcium concentrations should be closely monitored if a
patient initiates or discontinues therapy with a strong CYP3A4
inhibitor (e.g., ketoconazole, erythromycin, itraconazole.’’
The inclusion of these sentences might have helped improved
the recall of a classiﬁer. However, the method also led to the inclu-
sion of other sentences that could potentially reduce a classiﬁer’s
precision such as:
‘‘Less potent inhibitors include saquinavir, nefazodone, ﬂucona-
zole, grapefruit juice, ﬂuoxetine, ﬂuvoxamine, zileuton, and
clotrimazole.’’‘‘Example inducers include aminoglutethimide, carbamazepine,
nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.’’
While the use of the PDDI dataset was beneﬁcial for the Bui
pipeline with two PDDI datasets, it harmed its performance with
the MedLine dataset. We think that future NLP research should
explore methods to improve this simple approach to integrating
the merged PDDI dataset so that performance improvements on
any dataset will result.
The merged dataset makes it possible for the pharmacovigi-
lance text mining community to compare the representativeness
of NLP corpora for PDDI text extraction tasks. The low level of over-
lap identiﬁed between current NLP corpora and clinically oriented
datasets might be indicative that current corpora are not represen-
tative of all PDDIs. The merged dataset also speciﬁes elements that
future PDDI extraction tasks might want to include. For example,
none of the NLP sources included in this study provide severity
information or related drugs for the PDDIs.
While each PDDI source was developed for different purposes,
we found some evidence that making the sources interoperable
would indeed enable a better synthesis of PDDI knowledge. For
example, there were more than a dozen interactions from drug
product labeling sources that were also present in the ONC
High-priority or Non-interruptive lists. This means that, for these
PDDIs, an information retrieval system could use the merged data-
set to provide consensus recommendations on alert prioritization
to a reader of the electronic product label (e.g., a drug information
compendia editor). Similarly, three interactions from drug product
labeling were also present in the CredibleMeds dataset. Two of
these interactions involved the cardiovascular drug digoxin and
macrolide antibiotics erythromycin and clarithromycin. In both
cases, CredibleMeds provided information on management options
that were not present in the interactions extracted from the label.
To be speciﬁc, the following two quotes show all of the information
on the PDDI provided by the NLM Corpus and then the manage-
ment recommendations provided by CredibleMeds:
(NLM Corpus)
‘‘Erythromycin and clarithromycin (and possibly other macro-
lide antibiotics) and tetracycline may increase digoxin absorp-
tion in patients who inactivate digoxin by bacterial
metabolism in the lower intestine, so that digitalis intoxication
may result’’
(CredibleMeds)
‘‘Take Precautions
Consider Alternatives: Consider alternative antimicrobials that
do not inhibit P-glycoprotein (e.g., 2nd/3rd generation cepha-
losporins, penicillin, quinolones)
Monitor: If alternatives are not appropriate, evaluate patients for
evidence of digoxin toxicity (e.g., nausea, malaise, fatigue, visual
changes, headache, arrhythmias), with downward digoxin
dosage adjustments as needed. Also monitor for altered digoxin
effect when clarithromycin or erythromycin are changed in
dosage or discontinued. If digoxin is started in the presence of
one of these agents, consider conservative initial digoxin dosing.’’
There are other examples where combining the information
available across the multiple sources into the simple PDDI data
model provided much richer description of these interactions.
One example is the PDDI between clozapine and ﬂuoxetine –
DrugBank provided an unstructured text explanation of the PDDI
between clozapine and ﬂuoxetine. Additionally, DIKB enhanced
the description of this PDDI by providing both a URI to the PRO
ontology, indicating that the metabolic enzyme CYP2D6 is
involved in the interaction, and also citations to evidence in the
scientiﬁc literature (including product labeling) supporting the
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caution in Japanese product labels. This case is interesting
because, in theory, the mechanism of the PDDI could be used by
a computer to suggest alternate treatment strategy such as substi-
tuting ﬂuoxetine with an antidepressant (e.g., citalopram) that is
not a potent CYP2D6 inhibitor.
The previous example of inferring a plausible management
option from the merged information on the clozapine and ﬂuox-
etine PDDI suggests that there is great potential beneﬁt from link-
ing clinically useful PDDI information (e.g., effects, severity, and
management options) with the chemical and pharmacological
properties (e.g., chemical structure, function, pharmacokinetic
and pharmacodynamic properties) of not only the participating
drugs, but all related drugs. We think that such a representation
should also make an explicit and logically sound connection
between the drugs involved in a PDDI (usually pharmacologically
active molecules) and the pharmaceutical products that are pre-
scribed and administered to patients. For example, at the time of
this writing, DrugBank currently lists 164 PDDIs involving keto-
conazole.5 Unfortunately, DrugBank provides no way to infer that
most, if not all, of the PDDIs are relevant for only a handful of keto-
conazole drug products that are systemic rather than topical. Thus,
while drug-focused databases like DrugBank and KEGG provide a
one-stop shop for information regarding chemical structure, func-
tion, interactions, and clinical application, their data models tend
to conﬂate attributes of chemical entities with properties of complex
pharmaceutical products. Indeed, recent work on the Drug Ontology
(DrOn) suggests a compelling mechanism by which accurate
descriptions of drug composition, route of administration, and func-
tion can be achieved using orthogonal ontologies such as ChEBI and
the Protein Ontology [45]. We recently proposed a new approach to
building an ontology for representing PDDI knowledge and evidence
that we think might improve the utility of PDDI listings for clinical
purposes [46]. In future work, we plan to apply the merged PDDI
dataset from the current study to test and improve the ontology
which is currently in an early stage of development.
There was a signiﬁcant proportion of PDDIs from KEGG,
TWOSIDES, and the NDF-RT that we were unable to map to
DrugBank because we could ﬁnd no URI for one or both of the
involved drugs (Table 1). A query of the number of DrugBank drug
records that provide cross reference URIs to PubChem or KEGG
shows that the linkage between the data sources is currently
incomplete.6 Yet other cases involved drugs that were not in the
RxNorm to DrugBank mapping [40] perhaps because it was not pos-
sible to create the mapping when the dataset was created (fall 2014).
Regarding SemMedDB, we used ‘‘INTERACTS_WITH’’ relationships
for drug interactions in this study but there exist alternative predic-
tions that could potentially be used for inferring some drug interac-
tions and we might explore additional types of predictions in
SemMedDB for PDDIs in the future.
We also tested if the combined dataset would improve the per-
formance of a recently published PDDI pharmacovigilance proto-
col. The protocol performed best when using the combined CDM
model as a reference standard for PDDIs. We think that this is
because the integrated PDDI model was more representative of
the universe of all potential PDDIs and therefore led to a more gen-
erally predictive model. These preliminary results indicate that
merging PDDIs from all available public sources may be important
for PDDI pharmacovigilance.
Another interesting direction of future work is the improve-
ment of drug interaction information in Wikipedia by adding
expert-vetted PDDI data to Wikidata [47]. Wikipedia is easily5 http://www.DrugBank.ca/drugs/DB01026.
6 Of 6825 DrugBank drugs, 6100 contained PubChem xref URIs and 2535
contained KEGG drug or compound xref URIs.accessible, routinely used by clinicians for ﬁnding medical infor-
mation [48] and could play a signiﬁcant role in global health pro-
motion [49]. However, the quality of information on Wikipedia
was found to be lower than in some proprietary resources [50].
Wikidata is a recent addition to the Wikipedia infrastructure, pro-
viding an open, efﬁcient database for serving content to Wikipedia
in different languages. We are working on integrating high-quality
PDDI information to Wikidata and currently ﬁnishing the evalua-
tion of a prototype for making these data available in Wikipedia.4.1. Potential limitations
It is possible that our search missed some relevant sources,
especially sources that might be available in non-English speaking
countries. Also, it is possible that new sources have become avail-
able since the time we conducted the search. Our plans for future
work include continuing to update the merged dataset with newly
identiﬁed sources and making the data available as part of the Drug
Interaction Knowledge Base project [51].
We focused on the non-proprietary information sources rather
than commercially available PDDI sources. Both use PDDI content
obtained from a handful of public sources included drug product
labeling and the indexed scientiﬁc literature. While access to
PDDI data is similar between non-proprietary and commercially
available sources, they do differ in their efforts to assess the data
and put it into perspective for users. For example, some sources
use speciﬁc criteria for inclusion of PDDIs while others strive to
be all inclusive. Facilitating the gathering of PDDI data is an impor-
tant ﬁrst step, but must be followed by knowledgeable assessment
of the PDDI’s risk to patients to avoid the current problem of exces-
sive, inappropriate PDDI alerts. Improving the interoperability of
these sources might simplify drug interaction experts’ or compen-
dia editors’ task of acquiring all information known about a PDDI
and making better decisions regarding its potential to cause
patient harm. Moreover, the number of public PDDI sources has
grown in recent years and, with proper evaluation, the PDDIs that
they provide might enhance other widely used public information
systems such as Wikidata [47].
The NLP resources contained many instances of atypical and
error-prone drug group mentions in the PDDIs i.e. ‘‘drugs that are
actively secreted by the kidney has not been investigated in
humans’’, ‘‘drugs that do not require a similar titration’’,
‘‘live-attenuated vaccines’’, ‘‘drugs that can interfere with sinus
node function’’. As the deﬁnitions for all possible drugs in each
atypical drug group can be various and subjective to each reviewer,
the manual review was not feasible and beyond the scope of this
study. These challenges rise from the nature of the original data
sources independent of our data model. Use of atypical drug men-
tions in the NLP PDDIs makes it very difﬁcult if not impossible to
come up with a reasonable and widely agreed upon comprehensive
mapping to active ingredients, either manually or using automa-
tion. This is a critical issue that we think the NLP community needs
to be aware of and address if future tools are to be of real use to the
pharmacovigilance community. In the future, we will also investi-
gate new approaches for overcoming the mapping challenges.5. Conclusion
In this study, we combined all the publicly available sources of
PDDI information using a common data model after conducting a
comprehensive and broad search. The merged dataset consists of
the synthesis of 14 different sources including 5 sources obtained
from clinically-oriented information sources, 4 sources from
Natural Language Processing Corpora, and 5 sources from Bioinfo
rmatics/Pharmacovigilance information sources.
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and our analysis found out that there was little overlap and that
there is heterogeneity between the information provided by each
source. Another interesting ﬁnding was that most of the ONC
High Priority PDDIswere not included in comprehensive drug inter-
action data sources such as NDF-RT, KEGG, and DrugBank. Despite
this, the combined dataset provided a more complete overview of
the PDDIs and a richer deﬁnition of the PDDIs than the original
sources in cases where the PDDIs were noted in multiple resources.
Additionally, we investigated the cases where PDDI information
extracted from drug product labeling might be automatically aug-
mented by other sources. We also experimented with the use of
the combined dataset in a recently published PDDI pharmacovigi-
lance protocol. The results demonstrated an improvement on the
performance of the protocol.
As future work, we plan to improve the mapping mechanisms
and integrate high-quality PDDI information in the merged dataset
to Wikidata and make it available for a broader community of
stakeholders. Another future work is to make the combined dataset
accessible to humans and computer programs as Semantic Web
Linked Data.Conﬂict of interest
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